Cardiology

Explore the evolving landscape of heart failure endpoints, focusing on the significance of oral diuretic intensification in outpatient care.

Recent analyses detail the ongoing risk of hyperkalemia in heart failure patients, highlighting the importance of optimal medication dosing.

An analysis of data from the HELIOS-B trial indicated an overall reduction in GI events among the vutrisiran cohort compared to those receiving placebo.

Aficamten shows superior exercise capacity improvements over metoprolol for patients with oHCM.

100% of included participants were successfully defibrillated and exhibited 6-month improvements or stability in the majority of patients.

New 96-week data reveals aficamten's significant benefits for patients with nonobstructive hypertrophic cardiomyopathy.

Acoramidis significantly lowers cardiovascular event risk in ATTR-CM, emphasizing the need for early diagnosis & treatment.

Guideline-directed medical therapy and SGLT2i use has been associated with reduced total health care costs and a lower risk of hospitalization and death.

If this connection is proven, the gut microbiome may present an entirely new pathway for treatment and prevention of heart failure.

Patients taking multiple drugs simultaneously receive the same protective effect from finerenone, regardless of their degree of polypharmacy.

New research links marijuana use to higher readmission and mortality rates in heart failure patients.

Recent studies reveal finerenone's superior benefits over traditional MRAs in heart failure, showing reduced mortality and hospitalization rates.

A recent publication from the HFSA highlights obesity, chronic kidney disease, diabetes mellitus, and hypertension as major driving forces.

The extended indication includes children 1 to < 5 years of age with homozygous familial hypercholesterolemia.

Despite the global prevalence of hypercholesterolemia, only 11% of children receive lipid screening, leaving many cases undiagnosed.

Investigators have highlighted diabetes and obesity as leading drivers of steadily increasing global cardiovascular mortality rates.

A compiled list of the 8 most exciting presentations scheduled for the Heart Failure Society of American Annual Scientific Meeting 2025.

Less than optimal outcomes with ASCVD also increased healthcare resource utilization and costs.

Despite prior trials indicating the possibility, the AUSPICE study failed to display any difference in risk between patients receiving the vaccine versus placebo.

In a study, the prevalence of transthyretin cardiac amyloidosis reached 17% in Black men over 75 years old.

Findings from an analysis of GBD 2021 data highlight increases in the absolute number of ASCVD cases and deaths among the working-age population.

AKINESIS study finds kidney tubule biomarker IGFBP‑7 predicts 1-year death and heart failure readmission in acute heart failure patients.

New research supports fimasartan, atorvastatin, and ezetimibe combination to blood pressure and cholesterol levels.

Findings suggest post-stroke dysphagia is associated with adverse psychosocial outcomes at 3 months, emphasizing the need for comprehensive rehabilitation strategies.

Parent company CeleCor Therapeutics announced positive safety and efficacy endpoint data for their investigative GPIIb/IIIa inhibitor versus placebo.